Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
2 days ago
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.

Mepolizumab shows promise against hypereosinophilic syndrome

18 Dec 2020

Mepolizumab, a humanized monoclonal antibody that binds interleukin-5, can suppress flares in patients with hypereosinophilic syndrome (HES) without posing new safety concerns, reports a recent trial.

Researchers randomly assigned HES patients to receive either 300 mg of subcutaneous mepolizumab (n=54; mean age, 46.6 years) or placebo (n=54; mean age, 45.4 years). Study interventions were given every 4 weeks for 32 weeks. The primary endpoint was the proportion of patients who had experienced a flare over the study duration.

Forty-two patients experienced 65 flares over the duration of the study. The occurrence of at least one episode of flares was twice as frequent in placebo participants than in their mepolizumab counterparts (56 percent vs 28 percent; p=0.002).

Logistic regression analysis verified this, showing a significantly suppressed risk of flares among the mepolizumab-treated participants (odds ratio [OR], 0.28, 95 percent confidence interval [CI], 0.12–0.64; p=0.003). This effect was robust to sensitivity and posthoc analyses.

In terms of secondary endpoints, Kaplan-Meier estimates showed that the likelihood of experiencing a first flare episode during the treatment period was reduced by 66-percent in the mepolizumab arm (hazard ratio, 0.34, 95 percent CI, 0.18–0.67; p=0.002). Similarly, the adjusted annualized rate of flares was also 66-percent lower in mepolizumab patients (p<0.001), who also saw greater improvement in fatigue severity at 32 weeks compared with placebo participants (p=0.04).

These intervention efficacies did not come with additional safety signals. While the prevalence of on-treatment adverse events was high, rates did not vary between groups (89 percent vs 87 percent). Drug-related side effects were also only modestly more common in the mepolizumab group (22 percent vs 13 percent).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
2 days ago
Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.